Developing First-in-Class Protein Replacement Therapy for Rare, Genetic Disorder DEB

Lotus Tissue Repair, Inc. is developing its proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), a devastating orphan disease with no currently approved treatment options other than palliative care. The company’s innovative technology works to directly replace the deficient or dysfunctional collage type VII in DEB patients. Lotus was acquired by Shire PLC in 2013.

Year Invested: 2011

Associated Team Members

Neil Exter

Philip Reilly, M.D., J.D.
Venture Partner